SCHEDULE: Barclays Discloses 0.42% Stake in Core Scientific

Barclays PLC has reported a 0.42% beneficial ownership stake in Core Scientific Inc., holding 1,302,387 common shares as of December 31, 2025.

Summary

• Barclays PLC, a UK-based entity, filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Core Scientific Inc.
• The filing reports beneficial ownership of 1,302,387 shares of Core Scientific Inc. common stock.
• This ownership represents 0.42% of Core Scientific's outstanding common stock.
• Barclays PLC holds sole voting power over 1,298,420 shares and shared voting power over 3,967 shares.
• Barclays PLC holds sole dispositive power over 1,298,420 shares and shared dispositive power over 3,967 shares.
• The shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure, typical for institutional passive investments, providing transparency without indicating significant operational changes or strategic shifts for Core Scientific.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Core Scientific Inc.'s future performance or operations.

Management Comments

• The securities referred to were acquired and are held in the ordinary course of business.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that institutional filings like Schedule 13G provide transparency into significant ownership stakes, which can influence market perception. Barclays' stake, while below the 5% threshold for active investor filings, indicates a passive investment by a major financial institution.

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership in Core Scientific Inc.

Key Dates

Recommendation

The Schedule 13G filing by Barclays PLC indicates a passive beneficial ownership of 0.42% in Core Scientific Inc. This disclosure provides transparency regarding institutional holdings but does not present new information that would fundamentally alter the investment outlook or warrant a strong buy or sell recommendation. It confirms institutional interest without suggesting any strategic shifts or performance changes for Core Scientific.

Keywords

Barclays PLC, Core Scientific Inc, Schedule 13G, beneficial ownership, common stock, institutional ownership, SEC filing